Plerixafor 8HCl (AMD3100 8HCl)

Plerixafor 8HCl (AMD3100 8HCl) Basic information
Product Name:Plerixafor 8HCl (AMD3100 8HCl)
Synonyms:SID791;AMD3100;AMD3100 OCTAHYDROCHLORIDE;BISCYCLAM;JM3100;AMD3100 OCTAHYDROCHLORIDE HYDRATE ANHYDROUS;amd3100 octahydrochloride hydrate;1,1'-[1,4-Phenylenebis-(methylene)]-bis-(1,4,8,11-tetraazacyclotetradecane) octahydrochloride, min. 95 % (NMR)
CAS:155148-31-5
MF:C28H54N8
MW:502.78
EINECS:828-184-5
Product Categories:Inhibitors
Mol File:155148-31-5.mol
Plerixafor 8HCl (AMD3100 8HCl) Structure
Plerixafor 8HCl (AMD3100 8HCl) Chemical Properties
Melting point 188 - 193°C (dec.)
storage temp. Sealed in dry,Store in freezer, under -20°C
solubility H2O: ≥10 mg/mL, clear
form solid
color White
Water Solubility Soluble in water (100mM)
Stability:Stable for 1 year from date of purchase as supplied. Solutions in distilled water may be stored at -20°C for up to 2 months.
Safety Information
Safety Statements 22-24/25
WGK Germany 3
MSDS Information
Plerixafor 8HCl (AMD3100 8HCl) Usage And Synthesis
DescriptionPlerixafor (155148-31-5) is a highly selective CXCR4 antagonist (IC50 = 20-130 nM).1,2 Originally investigated as an HIV replication inhibitor.3 Plerixafor has been investigated for the treatment autoimmune diseases and various cancers.4 Clinically useful for the mobilization of hematopoietic stem cells in the treatment of blood cancers.
UsesPlerixafor Hydrochloride (1:8), is an immunostimulant used to mobilize hematopoietic stem cells in cancer patients. It is a hematopoietic stem cell (HSC) mobilizer that inhibits the CXCR4 chemokine receptor and blocks binding of its ligand, stromal cell-derived factor-1-α (SDF-1-α).
UsesPlerixafor 8HCl (AMD3100 8HCl) is the hydrochloride of Plerixafor, a chemokine receptor antagonist for CXCR4 and CXCL12-mediated chemotaxis with IC50 of 44 nM and 5.7 nM, respectively - See more at: http://www.selleckchem.com/products/plerixafor-8hcl-db06
UsesA specific CXCR4 antagonist.
General DescriptionA symmetrical bicyclam compound that antagonizes CXCL12 (SDF1) binding to CXCR4 (IC50 = 108 and 245 nM using rat and human CXCR4, respectively) and inhibits SDF1-induced Ca2+ flux (by 100% at 100 ng/ml in SUP-T1 and THP-1 cultures) as well as CXCR4-, but not CCR5-, mediated HIV infection (IC50 ≤200 nM), while enhancing the binding of SDF1 to CXCR7 (by ~60% at 1 mM with CXCR7-expressing HEK293T cells) and SDF1-induced β-arrestin recruitment to CXCR7 (EC50 = 6.48 and 11.8 nM, in the presence and absence of 10 μM AMD3100, respectively). Administration AMD3100 via intravenous infusion is also reported to result in hematopoietic stem cell mobilization in humans, dogs, and mice in vivo. Exhibits no inhibitory effects against chemokine-induced signaling via CXCR1/2/3 or CCR1/2/3/4/5/6/7/8/9.
Biological ActivityHighly selective CXCR4 chemokine receptor antagonist (IC 50 values are 0.02 - 0.13 and > 25 μ M for CXCR4 and all other chemokine receptors respectively). Switches inflammatory responses from Th2 to Th1 type and reduces airway hyperresponsiveness in a mouse model of asthma. Potently inhibits HIV-1 and HIV-2 replication in vitro (EC 50 = 4 - 35 nM) and mobilizes hematopoietic stem cells in vivo .
Biochem/physiol ActionsCell permeable: yes
Clinical UsePlerixafor hydrochloride, a chemokine CXCR4 (SDF-1) antagonist, was launched by Genzyme for the treatment of enhancing mobilization of hematopoietic stem cells for autologous transplantation in patients with lymphoma and enhancing mobilization of hematopoietic stem cells for transplantation in patients with multiple myeloma. Being a CXCR4 antagonist, a specific cellular chemokine receptor, plerixafor triggers the rapid movement of stem cells out of the bone marrow and into circulating blood where the stem cells can be collected for use in stem cell transplants. Regarding its use for cardiac applications, some clinical data suggests that the presence of stem cells circulating in the bloodstream or directly injected into the hearts of patients who have suffered a heart attack may result in improved cardiac function.
SynthesisA concise one-pot synthesis was achieved by a rather novel nitrogen protecting strategy. Tetraazacyclotetradecane 88 was protected as its phosphorotriamide 89 by reaction with POCl3 and Et3N in hot DMF. Without isolation, compound 89 was bis-alkylated with dibromide 90 in the presence of sodium carbonate in refluxing DMF overnight to give bis-phosphoramide 91. The crude dimeric bis-phosphoramide was hydrolyzed with 3 M HCl to afford plerixafor hydrochloride (XV) in 62¨C68% yield.

Synthesis_155148-31-5

storage-20°C (desiccate)
References1) Donzella, et al. (1998), AMD3100, A Small Molecule Inhibitor of HIV-1 Entry via the CXCR4 Co-Receptor; Nat. Med. 4 72 2) Hatse et al. (2002), Chemokine Receptor Inhibition by AMD3100 Is Strictly Confined to CXCR4; FEBS Lett. 527 255 3) Bridger et al. (1995), Synthesis and Structure-Activity Relationships of Phenylenebis(methylene)-linked Bis-Tetraazamacrocycles That Inhibit HIV Replication. Effects of Macrocyclic Ring Size and Substituents on the aromatic Linker; J. Med. Chem. 38 366 4) Wang et al. (2020), CXCR4 antagonist AMD3100 (plerixafor): from an impurity to a therapeutic agent; Pharmacol. Res. 159 105010
Plerixafor 8HCl (AMD3100 8HCl) Preparation Products And Raw materials
PLERIXAFOR 1,4,8,11-Tetrakis[(4-methylphenyl)sulfonyl]-1,4,8,11-tetraazacyclotetradecane Plerixafor Methylene Chloride Methyltriphenylphosphonium bromide N-Methyl-2-pyrrolidone Methylene Blue 1,4,8,11-TETRAAZACYCLOTETRADECANE 1,3-PROPANEDIAMINE,N,N'-BIS(2-AMINOETHYL), TETRAHYDROCHLORIDE Heptamethyldisilazane Dichloromethylphenylsilane METHYL-2-PYRROLIDONE N,N-Dimethyldodecylamine Tetradecane 4,4'-Diphenylmethane diisocyanate Hexamethyldisilazane 1-Benzyl-1,4,8,11-tetraazacyclotetradecane Plerixafor 8HCl (AMD3100 8HCl)

Email:[email protected] [email protected]
Copyright © 2024 Mywellwork.com All rights reserved.